Paris (France), January 13, 2022 – 6 p.m. CET – Onxeo SA (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereinafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms to fight rare or resistant cancers, today announces its financial calendar for fiscal year 2022.
2021 annual results: Wednesday, March 30, 2022
General meeting: Thursday, May 12, 2022
First-half 2022 results: Thursday, July 28, 2022
To receive all of ONXEO’s financial information in real time, send a request by email to [email protected] Your registration will be immediate.